Mobile

A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined h...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004586-13

A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-084 (208127/084)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•To evaluate the persistence of anti-HBs antibodies in terms of seroprotection rate and geometric mean concentrations (GMCs), 16 to 20 years after the first vaccine dose. •To evaluate the persistence of anti-HAV antibodies in terms of seropositivity rate and GMCs, 16 to 20 years after the first vaccine dose.

Critère d'inclusion

  • Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults)

Liens